150 related articles for article (PubMed ID: 9569080)
41. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
[TBL] [Abstract][Full Text] [Related]
42. [Laboratory and morphologic parameters in patients with lupus nephritis].
Rasković S; Bogić M; Perić-Popadić A; Stefanović L; Arandjelović S; Jovicić Z; Bolpacić J; Tomić-Spirić V
Srp Arh Celok Lek; 2002 Aug; 130 Suppl 3():38-41. PubMed ID: 12583312
[TBL] [Abstract][Full Text] [Related]
43. Prednisone monotherapy induced remission in a group of patients with membranous lupus nephritis.
Bitencourt Dias C; Pinheiro CC; Malafronte P; Titan S; Alves de Brito G; Gera Abrão J; Dos Santos Silva V; Toledo Barros R; Woronik V
Clin Nephrol; 2011 Jul; 76(1):57-63. PubMed ID: 21722606
[TBL] [Abstract][Full Text] [Related]
44. Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study.
Zavada J; Pesickova S; Rysava R; Olejarova M; Horák P; Hrncír Z; Rychlík I; Havrda M; Vítova J; Lukác J; Rovensky J; Tegzova D; Böhmova J; Zadrazil J; Hána J; Dostál C; Tesar V
Lupus; 2010 Oct; 19(11):1281-9. PubMed ID: 20605876
[TBL] [Abstract][Full Text] [Related]
45. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts.
Ruiz-Irastorza G; Ugarte A; Saint-Pastou Terrier C; Lazaro E; Iza A; Couzi L; Saenz R; Richez C; Porta S; Blanco P
Autoimmun Rev; 2017 Aug; 16(8):826-832. PubMed ID: 28564619
[TBL] [Abstract][Full Text] [Related]
46. Mizoribine therapy for patients with lupus nephritis: the association between peak mizoribine concentration and clinical efficacy.
Kuroda T; Hirose S; Tanabe N; Sato H; Nakatsue T; Ajiro J; Wada Y; Murakami S; Hasegawa H; Ito S; Sakatsume M; Nakano M; Gejyo F
Mod Rheumatol; 2007; 17(3):206-12. PubMed ID: 17564775
[TBL] [Abstract][Full Text] [Related]
47. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis.
Deng J; Huo D; Wu Q; Yang Z; Liao Y
Tohoku J Exp Med; 2012 Aug; 227(4):281-8. PubMed ID: 22820853
[TBL] [Abstract][Full Text] [Related]
48. [Mycophenolate mofetil in the treatment of lupus nephritis, in patients with failure, intolerance or relapses after treatment with steroids and cyclophosphamide].
Suría S; Checa MD
Nefrologia; 2007; 27(4):459-65. PubMed ID: 17944583
[TBL] [Abstract][Full Text] [Related]
49. [Severe nephrotic syndrome with reversible acute kidney failure in lupus-associated membranous nephropathy].
Pauli-Magnus C; Mettang T; Kuhlmann U
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):788-92. PubMed ID: 10414228
[TBL] [Abstract][Full Text] [Related]
50. Long-term data on tacrolimus treatment in lupus nephritis.
Yap DY; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM
Rheumatology (Oxford); 2014 Dec; 53(12):2232-7. PubMed ID: 24996908
[TBL] [Abstract][Full Text] [Related]
51. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial.
Cardiel MH; Tumlin JA; Furie RA; Wallace DJ; Joh T; Linnik MD;
Arthritis Rheum; 2008 Aug; 58(8):2470-80. PubMed ID: 18668592
[TBL] [Abstract][Full Text] [Related]
52. Moderator's view: The use of calcineurin inhibitors in the treatment of lupus nephritis.
Kronbichler A; Neumann I; Mayer G
Nephrol Dial Transplant; 2016 Oct; 31(10):1572-6. PubMed ID: 27591329
[TBL] [Abstract][Full Text] [Related]
53. [The use of measuring serum soluble IL-2 receptor levels in cyclosporine-A treated lupus nephritis].
Zheng X; Lin M; Cui X; Yao Q; Zhou G; Guo Z
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Sep; 26(3):338-41. PubMed ID: 8586406
[TBL] [Abstract][Full Text] [Related]
54. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
[TBL] [Abstract][Full Text] [Related]
55. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
[TBL] [Abstract][Full Text] [Related]
56. Guillain-Barré syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment.
van Laarhoven HW; Rooyer FA; van Engelen BG; van Dalen R; Berden JH
Nephrol Dial Transplant; 2001 Apr; 16(4):840-2. PubMed ID: 11274284
[No Abstract] [Full Text] [Related]
57. Presentation and Treatment Outcomes of 100 Lupus Nephritis Patients: Single Center Study.
Faroque MO; Hadiuzzaman KM; Islam SF; Hossain RM; Islam MN; Ahmed AH; Ahmed PI; Alam MR
Mymensingh Med J; 2016 Apr; 25(2):308-15. PubMed ID: 27277365
[TBL] [Abstract][Full Text] [Related]
58. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis.
Johns KR; Littlejohn GO
J Rheumatol; 1999 Oct; 26(10):2110-3. PubMed ID: 10529125
[TBL] [Abstract][Full Text] [Related]
59. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis.
Yee CS; Gordon C; Dostal C; Petera P; Dadoniene J; Griffiths B; Rozman B; Isenberg DA; Sturfelt G; Nived O; Turney JH; Venalis A; Adu D; Smolen JS; Emery P
Ann Rheum Dis; 2004 May; 63(5):525-9. PubMed ID: 15082482
[TBL] [Abstract][Full Text] [Related]
60. Effect of cyclophosphamide pulse therapy in a patient with intractable lupus nephritis.
Shibasaki T; Matsumoto H; Ohno I; Matsuda H; Kanai T; Ishimoto F; Sakai O
Jpn J Med; 1990; 29(4):414-6. PubMed ID: 2273625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
